Treatment Options After FOLFIRINOX Failure in Rectal Cancer

Second-Line Treatment Strategy

The National Comprehensive Cancer Network recommends switching to an oxaliplatin-based regimen (FOLFOX or CAPOX) combined with bevacizumab after FOLFIRINOX failure in metastatic rectal cancer patients 1, 2
FOLFOX or CAPOX with bevacizumab is the preferred second-line option after FOLFIRINOX failure, as it improves overall survival 1, 2
Bevacizumab continuation beyond progression improves overall survival (11.2 vs 9.8 months; HR 0.81, p=0.0062) in patients with metastatic rectal cancer 1
Aflibercept or ramucirumab combined with FOLFIRI can be used as alternatives to bevacizumab in second-line treatment 2

For RAS wild-type tumors with left-sided primary location, consider cetuximab or panitumumab plus irinotecan (or as single agents if combination not tolerated) 1, 2
For RAS wild-type tumors with right-sided primary location, prioritize bevacizumab-containing regimens over anti-EGFR therapy 3
For BRAF V600E-mutated tumors, encorafenib plus cetuximab is the recommended option in second or third line (ESMO-MCBS score: 4) 4, 2

Regorafenib (160 mg daily, days 1-21 of 28-day cycles) is FDA-approved for patients previously treated with fluoropyrimidines, oxaliplatin, irinotecan, anti-VEGF therapy, and (if RAS wild-type) anti-EGFR therapy 4, 2
Trifluridine/tipiracil (35 mg/m² twice daily, days 1-5 and 8-12 every 28 days) is an alternative oral agent with similar indications to regorafenib 4, 2
Combination of trifluridine/tipiracil with bevacizumab significantly prolongs overall survival and progression-free survival compared to monotherapy 4

For HER2-amplified tumors (2-5% of colorectal cancers), consider trastuzumab plus pertuzumab, trastuzumab plus lapatinib, or trastuzumab deruxtecan in third-line or later 4
For MSI-H/dMMR tumors, ipilimumab-nivolumab is recommended after first-line chemotherapy failure (ESMO-MCBS score: 3) 2

Do not use capecitabine monotherapy, mitomycin, interferons, taxanes, methotrexate, pemetrexed, sunitinib, sorafenib, erlotinib, or gemcitabine as salvage therapy—these have not shown efficacy in this setting 1
The order of receiving fluoropyrimidines, oxaliplatin, and irinotecan does not significantly impact overall survival, but exposure to all three agents during the continuum of care correlates with improved median survival 1
Rechallenge with anti-EGFR antibodies may be considered in selected RAS wild-type patients who initially responded 2

Perform radiological evaluation every 8-12 weeks with CT or MRI and CEA levels during active treatment 2